1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
Shanrong Biotechnology Corp.

Shanrong Biotechnology Corp.

SRBT
Shanrong Biotechnology Corp.US flagOther OTC
0.00
USD
- -
- -
298.00Market Cap
2008 Y
2008 Y
2009 Y
TTM
Revenue per Share
- -
2.18
- -
4.14
Basic EPS, GAAP
-0.93
-8.55
- -
-15.88
Free Cash Flow per Basic Share
-1.07
-4.58
- -
-2.46
Dividend per Share
- -
- -
- -
- -
Book Value per Share
-2.09
-16.7
- -
-32.47
Tangible Book Value per Share
-0.4
-11.48
- -
-12.44
Basic Weighted Avg Shares
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
1
1
1
Operating Margin (%)
- -
-348.6
-362.96
-371.83
Depreciation Expense
- -
- -
- -
- -
Net Income, GAAP
- -
-3
-5
-5
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
- -
-392.78
-383.32
-383.32
Working Capital
- -
-4
-4
-4
LT Debt
- -
- -
- -
- -
Total Equity
- -
-4
-4
-4
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
25.71
Return on Common Equity (%)
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'09
Sep'09
Dec'09
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'09
Sep'09
Dec'09
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
4
Payables & Accruals
2
2
2
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
8.99%
Free Cash Flow
- -
- -
-45.92%
Net Income, GAAP
- -
- -
86.7%
Sales/Revenue/Turnover
- -
- -
91.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
1
2009
- -
1
- -
- -
1

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2007
-0.01
-0.02
-0.13
- -
- -
2008
- -
- -
- -
- -
-8.55
2009
-2.34
-1.4
0.57
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Colonel Timothy D. Ringgold
Full Time Employees
3
Sector
Financial Services
Industry
Shell Companies
Address
9350 Wilshire Boulevard Beverly Hills CA United States of America 90212
IPO Date
Feb 9, 2018
Website
shanrongbio.com
Similar Companies
American Acquisition Opportunity Inc. (AMAOW)
CO2 Energy Transition Corp. (NOEMW)
MDH Acquisition Corp. (MDH-UN)
ScION Tech Growth I (SCOAU)
Lucid Group, Inc. (CCIV)
Primavera Capital Acquisition Corporation (PV-UN)
Business
Shanrong Biotechnology Corp. is a holding company focused on select biotechnology, health, and wellness operations. The company owns and operates three patents related to melatonin-based pharmaceutical formulations, including a long-lasting preparation of stable intravenous melatonin injectable for treating sepsis, bacterial, and inflammatory pathologies; new melatonin formulations for chemotherapy-resistant tumors targeting cancers such as head and neck, prostate, breast, ovarian, and melanoma. Founded in 2001 and headquartered in Shanghai, China, Shanrong Biotechnology formally relaunched its operations in October 2022 after a period of inactivity, transforming into a holding company dedicated to biotechnology and wellness industry ventures. The company is actively pursuing growth through a preliminary all-stock acquisition agreement with a European-based biotechnology firm, which would become a wholly owned subsidiary upon completion. Since the relaunch, Shanrong has invested in reviewing and renegotiating agreements with partners, customers, vendors, licensors, and conducting due diligence on potential joint ventures and acquisitions to strengthen its position in the health and wellness sector. No products or services were directly generating revenue as of the latest updates, with clinical trials for the patented pharmaceutical preparations ongoing or pending further capital financing for Phase III trials. Shanrong's business model integrates licensing, research, and development within biotechnology markets primarily across Europe and China.